ArticleScientific reports2025
Dual redox effects of 2,6-bis-(4-hydroxyl-3-methoxybenzylidene) cyclohexanone (BHMC) on human liver cancer cells, HepG2 via ROS, glutathione and Nrf2/Keap1 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurcumin has demonstrated significant potential as a chemoprotective agent by inducing death in malignant cells while exhibiting selective cytotoxicity toward normal cells. However, curcumin has limited bioavailability which hindered its full potential. Thus, 2,6-bis-(4-hydroxyl-3-methoxybenzylidene) cyclohexanone (BHMC), a curcuminoid derivative is produced by eliminating unstable β-diketone component, transformed it with double bonds while retaining the phenolic hydroxyl group. Of note, BHMC triggers greater cytotoxic effect via inducing higher oxidative stress damage through reactive oxygen species (ROS)-mediated pathway. Increased of ROS cause the redox buffering system to collapse, resulting in lipid peroxidation and disintegration of the mitochondrial membrane potential, which eventually causes cell death in malignant cells. METHODOLOGY: Total antioxidant activity was determined using Ferric Reducing Antioxidant Power (FRAP) assay biochemically and on HepG2 cells. Intracellular ROS was then measured using 2',7'-Dichlorodihydrofluorescein diacetate (DCFDA) assay which was confirmed by determined the level of intracellular glutathione. The expression of Keap1 and Nrf2 was further analysed using immunocytochemistry. RESULT AND DISCUSSION: BHMC exhibits antioxidant properties by demonstrating greater total antioxidant activity both biochemically and in HepG2 cells. Further analysis shows that BHMC significantly reduces intracellular ROS levels in HepG2 cells at low concentrations of 15 µM after 18 h and 10 µM after 24 h compared to untreated. However, at a higher concentration of 20 µM, BHMC induces oxidative stress like curcumin by lowering the ratio of reduced glutathione to glutathione disulfide (GSH/GSSG) and upregulating Nrf2 expression. The effects of BHMC are dose-dependent, with the compound acting as either an antioxidant or pro-oxidant depending on the concentrations.
conclusionBHMC exhibits potent antioxidant activity by reducing harmful reactive oxygen species and boosting protective glutathione levels in cells at low doses, but at higher doses, it may induce oxidative stress. These findings suggest BHMC's dose-dependent role in balancing antioxidant and pro-oxidant effects, highlighting its potential for further therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.